Skip to main content

Table 1 Comparison of patient- and tumour characteristics in the non-ABR and the ABR group

From: Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer

Variable Non-ABR (n = 1841) ABR (n = 485) p-value
n % n %  
Age at mastectomy, median (range) 55 (23–71)   47 (24–71)   <  0.001*
 - Missing data 0   0   
NPI, median (range) 4.6 (2.0–9.1)   4.5 (2.0–8.2)   0.007*
 - Missing data 221   42   
Invasive tumour size in mm, median (range) 30 (0–180)   25 (0–160)   <  0.001*
 - Missing data 105   18   
In situ tumour size in mm, median (range) 49 (0–170)   49 (0–170)   0.965
 - Missing data 572   132   
Tumour grade      0.663
 - 1 151 8 45 9  
 - 2 816 45 206 43  
 - 3 850 47 225 47  
 - Missing data 24   9   
Lymph node status      0.020*
 - Negative 739 47 229 54  
 - Positive 817 53 196 46  
 - Missing data 285   60   
Lymphovascular invasion      0.945
 - No 872 67 222 67  
 - Yes 432 33 109 33  
 - Missing data 537   154   
Tumour type      0.290
 - IDC 1360 74 372 77  
 - ILC 325 18 71 15  
 - Other 156 8 42 9  
 - Missing data 0   0   
ER/PR      0.948
 - Negative 389 21 103 22  
 - Positive 1424 79 374 78  
 - Missing data 28   8   
Her-2      0.892
 - Negative 1419 81 375 80  
 - Positive 342 19 92 20  
 - Missing data 80   18   
Neoadjuvant treatment      
 - Yes 275 15 56 12 0.057
 - No 1566 85 429 88  
 - Missing data 0   0   
  1. Variables presented with percentages are analysed using a Chi-square test. Variables summarized by medians and range are analysed using a Mann-Whitney U test. All reported p-values are two-sided
  2. NPI Nottingham Prognostic Index, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER oestrogen receptor, PR progesterone receptor, Her-2 Human epidermal growth factor receptor
  3. *denotes statistical significance (p < 0.05)